Risk of Second Primary Malignancies in Patients With Follicular Lymphoma: A United States Population-based Study

Smith Giri, Vijaya R Bhatt, Vivek Verma, Ranjan Pathak, Robert G Bociek, Julie Marie Vose, James Olen Armitage

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Follicular lymphoma (FL) is a common low-grade lymphoma with excellent long-term survival in the present era. We used the Surveillance, Epidemiology, and End Results registry to identify patients with FL from 1992 to 2010 and study the incidence and risk factors for the development of second primary malignancies (SPMs). During a median follow-up period of 71 months, 1540 patients (9.9%) developed SPMs, with a cumulative incidence of 11% at 10 years and an increased risk of both hematologic and solid malignancies. This risk was significantly increased among patients aged > 65 years, males, and those receiving radiation therapy. Background With the improving outcomes of patients with follicular lymphoma (FL), it is imperative to focus on survivorship issues, including the development of second primary malignancies (SPMs). We used a large US database to measure the risk of SPMs among FL survivors. Materials and Methods We used the Surveillance, Epidemiology, and End Results-13 registry to identify FL patients from 1992 to 2011. We calculated the risk of SPMs, developing ≥ 6 months after diagnosis, using the standardized incidence ratio (SIR) and absolute excess risk. We calculated the cumulative incidence of SPMs using the competing risk method and risk factors for SPMs using univariate and multivariate methods. Results Of a total of 15,517 patients with FL followed up for a median of 71 months, 1540 (9.9%) developed SPMs, with a SIR of 1.08 and absolute excess risk of 11.3 per 10,000 person-years. A significantly increased risk was noted for Hodgkin lymphoma (SIR, 5.85), acute myeloid leukemia (SIR, 4.88), and the following sites: oral cavity and pharynx (SIR, 1.43), stomach (SIR, 1.43), lung and bronchus (SIR, 1.35), melanoma of skin (SIR, 1.38), other nonepithelial cancers of the skin (SIR, 2.88), urinary bladder (SIR, 1.24), and kidney/renal pelvis (SIR, 1.43). The cumulative incidence of SPMs was 11.06% at 10 years. Multivariate regression showed that age > 65 years (SIR, 1.57; P < .001), male gender (SIR, 1.43; P < .001), and receipt of radiation (SIR, 1.24; P = .001) predicted a higher rate of SPMs. Conclusion Patients with FL have increased risk of both hematologic and solid malignancies. Risk factors for SPMs include advanced age, male gender, and receipt of radiation therapy.

Original languageEnglish (US)
Pages (from-to)569-574
Number of pages6
JournalClinical Lymphoma, Myeloma and Leukemia
Volume17
Issue number9
DOIs
StatePublished - Sep 2017

Fingerprint

Follicular Lymphoma
Second Primary Neoplasms
Incidence
Population
Kidney Pelvis
Hematologic Neoplasms
Registries
Epidemiology
Radiotherapy
Skin Neoplasms
Bronchi

Keywords

  • Cumulative incidence
  • FL
  • Risk factors
  • Second primary malignancies
  • Survivorship

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

@article{4529264d854b47b19691a6337484add2,
title = "Risk of Second Primary Malignancies in Patients With Follicular Lymphoma: A United States Population-based Study",
abstract = "Follicular lymphoma (FL) is a common low-grade lymphoma with excellent long-term survival in the present era. We used the Surveillance, Epidemiology, and End Results registry to identify patients with FL from 1992 to 2010 and study the incidence and risk factors for the development of second primary malignancies (SPMs). During a median follow-up period of 71 months, 1540 patients (9.9{\%}) developed SPMs, with a cumulative incidence of 11{\%} at 10 years and an increased risk of both hematologic and solid malignancies. This risk was significantly increased among patients aged > 65 years, males, and those receiving radiation therapy. Background With the improving outcomes of patients with follicular lymphoma (FL), it is imperative to focus on survivorship issues, including the development of second primary malignancies (SPMs). We used a large US database to measure the risk of SPMs among FL survivors. Materials and Methods We used the Surveillance, Epidemiology, and End Results-13 registry to identify FL patients from 1992 to 2011. We calculated the risk of SPMs, developing ≥ 6 months after diagnosis, using the standardized incidence ratio (SIR) and absolute excess risk. We calculated the cumulative incidence of SPMs using the competing risk method and risk factors for SPMs using univariate and multivariate methods. Results Of a total of 15,517 patients with FL followed up for a median of 71 months, 1540 (9.9{\%}) developed SPMs, with a SIR of 1.08 and absolute excess risk of 11.3 per 10,000 person-years. A significantly increased risk was noted for Hodgkin lymphoma (SIR, 5.85), acute myeloid leukemia (SIR, 4.88), and the following sites: oral cavity and pharynx (SIR, 1.43), stomach (SIR, 1.43), lung and bronchus (SIR, 1.35), melanoma of skin (SIR, 1.38), other nonepithelial cancers of the skin (SIR, 2.88), urinary bladder (SIR, 1.24), and kidney/renal pelvis (SIR, 1.43). The cumulative incidence of SPMs was 11.06{\%} at 10 years. Multivariate regression showed that age > 65 years (SIR, 1.57; P < .001), male gender (SIR, 1.43; P < .001), and receipt of radiation (SIR, 1.24; P = .001) predicted a higher rate of SPMs. Conclusion Patients with FL have increased risk of both hematologic and solid malignancies. Risk factors for SPMs include advanced age, male gender, and receipt of radiation therapy.",
keywords = "Cumulative incidence, FL, Risk factors, Second primary malignancies, Survivorship",
author = "Smith Giri and Bhatt, {Vijaya R} and Vivek Verma and Ranjan Pathak and Bociek, {Robert G} and Vose, {Julie Marie} and Armitage, {James Olen}",
year = "2017",
month = "9",
doi = "10.1016/j.clml.2017.06.028",
language = "English (US)",
volume = "17",
pages = "569--574",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "9",

}

TY - JOUR

T1 - Risk of Second Primary Malignancies in Patients With Follicular Lymphoma

T2 - A United States Population-based Study

AU - Giri, Smith

AU - Bhatt, Vijaya R

AU - Verma, Vivek

AU - Pathak, Ranjan

AU - Bociek, Robert G

AU - Vose, Julie Marie

AU - Armitage, James Olen

PY - 2017/9

Y1 - 2017/9

N2 - Follicular lymphoma (FL) is a common low-grade lymphoma with excellent long-term survival in the present era. We used the Surveillance, Epidemiology, and End Results registry to identify patients with FL from 1992 to 2010 and study the incidence and risk factors for the development of second primary malignancies (SPMs). During a median follow-up period of 71 months, 1540 patients (9.9%) developed SPMs, with a cumulative incidence of 11% at 10 years and an increased risk of both hematologic and solid malignancies. This risk was significantly increased among patients aged > 65 years, males, and those receiving radiation therapy. Background With the improving outcomes of patients with follicular lymphoma (FL), it is imperative to focus on survivorship issues, including the development of second primary malignancies (SPMs). We used a large US database to measure the risk of SPMs among FL survivors. Materials and Methods We used the Surveillance, Epidemiology, and End Results-13 registry to identify FL patients from 1992 to 2011. We calculated the risk of SPMs, developing ≥ 6 months after diagnosis, using the standardized incidence ratio (SIR) and absolute excess risk. We calculated the cumulative incidence of SPMs using the competing risk method and risk factors for SPMs using univariate and multivariate methods. Results Of a total of 15,517 patients with FL followed up for a median of 71 months, 1540 (9.9%) developed SPMs, with a SIR of 1.08 and absolute excess risk of 11.3 per 10,000 person-years. A significantly increased risk was noted for Hodgkin lymphoma (SIR, 5.85), acute myeloid leukemia (SIR, 4.88), and the following sites: oral cavity and pharynx (SIR, 1.43), stomach (SIR, 1.43), lung and bronchus (SIR, 1.35), melanoma of skin (SIR, 1.38), other nonepithelial cancers of the skin (SIR, 2.88), urinary bladder (SIR, 1.24), and kidney/renal pelvis (SIR, 1.43). The cumulative incidence of SPMs was 11.06% at 10 years. Multivariate regression showed that age > 65 years (SIR, 1.57; P < .001), male gender (SIR, 1.43; P < .001), and receipt of radiation (SIR, 1.24; P = .001) predicted a higher rate of SPMs. Conclusion Patients with FL have increased risk of both hematologic and solid malignancies. Risk factors for SPMs include advanced age, male gender, and receipt of radiation therapy.

AB - Follicular lymphoma (FL) is a common low-grade lymphoma with excellent long-term survival in the present era. We used the Surveillance, Epidemiology, and End Results registry to identify patients with FL from 1992 to 2010 and study the incidence and risk factors for the development of second primary malignancies (SPMs). During a median follow-up period of 71 months, 1540 patients (9.9%) developed SPMs, with a cumulative incidence of 11% at 10 years and an increased risk of both hematologic and solid malignancies. This risk was significantly increased among patients aged > 65 years, males, and those receiving radiation therapy. Background With the improving outcomes of patients with follicular lymphoma (FL), it is imperative to focus on survivorship issues, including the development of second primary malignancies (SPMs). We used a large US database to measure the risk of SPMs among FL survivors. Materials and Methods We used the Surveillance, Epidemiology, and End Results-13 registry to identify FL patients from 1992 to 2011. We calculated the risk of SPMs, developing ≥ 6 months after diagnosis, using the standardized incidence ratio (SIR) and absolute excess risk. We calculated the cumulative incidence of SPMs using the competing risk method and risk factors for SPMs using univariate and multivariate methods. Results Of a total of 15,517 patients with FL followed up for a median of 71 months, 1540 (9.9%) developed SPMs, with a SIR of 1.08 and absolute excess risk of 11.3 per 10,000 person-years. A significantly increased risk was noted for Hodgkin lymphoma (SIR, 5.85), acute myeloid leukemia (SIR, 4.88), and the following sites: oral cavity and pharynx (SIR, 1.43), stomach (SIR, 1.43), lung and bronchus (SIR, 1.35), melanoma of skin (SIR, 1.38), other nonepithelial cancers of the skin (SIR, 2.88), urinary bladder (SIR, 1.24), and kidney/renal pelvis (SIR, 1.43). The cumulative incidence of SPMs was 11.06% at 10 years. Multivariate regression showed that age > 65 years (SIR, 1.57; P < .001), male gender (SIR, 1.43; P < .001), and receipt of radiation (SIR, 1.24; P = .001) predicted a higher rate of SPMs. Conclusion Patients with FL have increased risk of both hematologic and solid malignancies. Risk factors for SPMs include advanced age, male gender, and receipt of radiation therapy.

KW - Cumulative incidence

KW - FL

KW - Risk factors

KW - Second primary malignancies

KW - Survivorship

UR - http://www.scopus.com/inward/record.url?scp=85022083275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85022083275&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2017.06.028

DO - 10.1016/j.clml.2017.06.028

M3 - Article

C2 - 28709798

AN - SCOPUS:85022083275

VL - 17

SP - 569

EP - 574

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 9

ER -